-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Indinavir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/150378-17-9.gif)
| Category | HIV Protease |
| CAS | 150378-17-9 |
| Description | Indinavir is a member of the novel hydroxyaminopentane amide class of HIV-1 protease inhibitors. Indinavir is used as an antiviral. |
Product Information
| Synonyms | Crixivan; MK-639; L-735524; MK639; L735524; MK 639; L 735524 |
| IUPAC Name | (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide |
| Molecular Weight | 613.79 |
| Molecular Formula | C36H47N5O4 |
| Canonical SMILES | CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5 |
| InChI | InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1 |
| InChIKey | CBVCZFGXHXORBI-PXQQMZJSSA-N |
| Boiling Point | 831.6±75.0 °C at 760 mmHg |
| Melting Point | 150-153ºC |
| Flash Point | 456.8±37.1 °C |
| Purity | >98% |
| Density | 1.2±0.1 g/cm3 |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Application | HIV Protease Inhibitors |
| Storage | Store at -20°C |
| Complexity | 952 |
| Exact Mass | 613.36280500 |
| Index Of Refraction | 1.629 |
| In Vitro | Indinavir (0-50 µM; 18 h) blocks lymphocyte cell cycle in G0/G1 phase in PBMCs cells and impairs lymphoproliferative responses. Indinavir (40 µM-40 nM; 5 days) inhibits cell invasion and (40 µM-40 nM; 48 h) MMPs-2 activation of the Huh7 and SK-HEP-1 hepatocarcinoma cells in vitro. |
| In Vivo | Indinavir (70 mg/kg; i.g.; once a day for 3 weeks) inhibits the growth of hepatocarcinoma cells in vivo. |
| PSA | 118.03000 |
| Target | HIV; HIV Protease; Apoptosis; MMP; SARS-CoV |
| Vapor Pressure | 0.0±3.2 mmHg at 25°C |
| XLogP3-AA | 2.8 |
